Clearstead Advisors’s Larimar Therapeutics LRMR Stock Holding History

Clearstead Advisors’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.38K	Buy	1,765 +265	+18%	+$1.05K	﹤0.01%	2171
2026 Q1	$6.75K	Hold	1,500	–	–	﹤0.01%	1687
2025 Q4	$5.71K	Sell	1,500 -1,210	-45%	-$4.71K	﹤0.01%	1998
2025 Q3	$8.75K	Buy	2,710 +56	+2%	+$210	﹤0.01%	1964
2025 Q2	$7.67K	Buy	2,654 +1,154	+77%	+$2.67K	﹤0.01%	1978
2025 Q1	$3.23K	Hold	1,500	–	–	﹤0.01%	1816
2024 Q4	$5.8K	Hold	1,500	–	–	﹤0.01%	1688
2024 Q3	$9.82K	Hold	1,500	–	–	﹤0.01%	1582
2024 Q2	$10.9K	Buy	+1,500	New	+$11.5K	﹤0.01%	1537

Other funds holding LRMR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

CSP

Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return

Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

NLP

Next Level Private Harrison, New York $511M AUM 30.94% 1-Year Est. Return

Clearstead Advisors's LRMR Position: Q2 2026 in Review

Clearstead Advisors increased its Larimar Therapeutics (LRMR) stake by 18% in Q2 2026, buying an estimated $1.05K and bringing the position to 1,765 shares worth $5.38K. The position accounts for ﹤0.01% of the portfolio, ranked #2171.

Clearstead Advisors first reported a position in LRMR in Q2 2024 and has held it in 9 quarters since. The position peaked at $10.9K in Q2 2024. 50 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

Clearstead Advisors held 1,765 shares of Larimar Therapeutics worth $5.38K as of Q2 2026.
Clearstead Advisors bought 265 Larimar Therapeutics shares in Q2 2026, an estimated $1.05K.
Larimar Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2171 holding.
Clearstead Advisors first reported a position in Larimar Therapeutics in Q2 2024 and has held it in 9 quarters since.
Clearstead Advisors's Larimar Therapeutics position peaked at $10.9K in Q2 2024.
50 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.